Bitopertin Phase 3 Trial Achieved Primary and Secondary Endpoints
Biopharmaceutical Disc Medicine reports successful APOLLO trial for bitopertin, securing a pivotal milestone. The positive data supports the planned resubmission of the NDA to the FDA for the treatment of erythropoietic protoporphyria.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed